Held
RXO · RXO, Inc.
Last analysed ·
Against its published line
1 name has closed through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 10 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-07-31 at medium conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-10 and is not part of the scored record.
Current thesis
Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.
Kill line
A weekly close below $24 loses the May–June breakout shelf and consolidation base; secondary breaks are Q2 adjusted EBITDA (~2026-08-05) printing below the $27–37M guide floor, or the RXO Curve spot index rolling over.
Pick status
Invalidated resolved published kill line fired How this is scored →Latest analysis and events for RXO —
As of 10 September 2026, the latest FrontierPicks analysis for RXO, Inc. (RXO): Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.
Kill line: A weekly close below $24 loses the May–June breakout shelf and consolidation base; secondary breaks are Q2 adjusted EBITDA (~2026-08-05) printing below the $27–37M guide floor, or the RXO Curve spot index rolling over.
Next dated event on file: — catalyst in 5d.
Current Thesis
RXO’s freight-margin recovery requires Q3 2026 earnings to meet guidance and a weekly close above the former $24 shelf before a daily close below $19.79 ends the recovery hypothesis. Management’s 2026-08-06 guidance called for adjusted earnings before interest, taxes, depreciation and amortisation (adjusted EBITDA) of $35–45 million. The adjusted market close of $20.04 on 2026-09-09 leaves the price requirement unresolved.
The substantive update is operational: RXO reported on 2026-09-09 that August truckload gross profit per load increased more than 10% against July, exceeding its earlier outlook. This strengthens the earnings argument without establishing a completed price recovery. RXO’s September 9 update
As a price-structure inference, the narrative is dead in its former breakout form: the 2026-08-14 weekly close of $23.52 breached the original $24 invalidation condition. The narrower recovery hypothesis remains separate and unconfirmed; September’s operating improvement does not reverse that historical failure.
Bullish and bearish views on RXO, Inc.
The model's bull view on RXO, Inc. (RXO), in brief: Quarterly earnings exceeded management guidance. The bear view: Market confirmation remains absent. Through 2026-09-09, the adjusted price series shows a three-month decline of 30.3% and a close 31.6% below its 52-week high. The $20.04 close remains below the former $24 shelf despite the August earnings improvement. Cash conversion… Both cases follow in full.
Bull Case
- Quarterly earnings exceeded management guidance. RXO’s 2026-08-06 earnings release reported Q2 adjusted EBITDA of $40 million against guidance of $27–37 million. The continuation case fails if Q3 adjusted EBITDA falls below the subsequently guided $35 million floor.
- August load economics beat expectations. RXO’s 2026-09-09 update reported stronger August profit per load while maintaining expected Q3 truckload volume growth in the low-to-mid single digits year over year. These are preliminary operating indicators; reported Q3 gross profit per load declining sequentially would contradict the margin-continuation argument. Company update
Bear Case
- Market confirmation remains absent. Through 2026-09-09, the adjusted price series shows a three-month decline of 30.3% and a close 31.6% below its 52-week high. The $20.04 close remains below the former $24 shelf despite the August earnings improvement.
- Cash conversion constrains the recovery. RXO’s 2026-08-06 Q2 disclosures reported roughly $70 million of working-capital drag and bank-adjusted net leverage of 4.1 times. Q3 leverage above 4.1 times would weaken the argument that improving earnings are repairing the financial position.
- Partnership economics remain undisclosed. The 2026-09-03 Enterprise Purchasing Group announcement named RXO its exclusive full-truckload and less-than-truckload provider; contemporaneous Benzinga coverage said terms were undisclosed. No quantified earnings contribution supports an uplift to the recovery case.
Setup & Price Structure
The 2026-09-09 adjusted close was $20.04, compared with the published September 2 closing low of $19.79. The 14-period relative strength index (RSI) measured 36.4 on September 9. Neither observation establishes a completed base; confirmation requires a weekly close above the former $24 shelf before the published invalidation condition occurs.
The positioning observation remains dated: exchange short-interest data for the 2026-07-31 settlement showed 8.85% of float short and 6.6 days to cover. That historical snapshot cannot establish current squeeze pressure. No current moving-average measurement or retail-participation series is available, so neither extension above a rising average nor expanding crowd participation is established.
Catalyst Calendar (next 30 days)
- 2026-09-16 — Morgan Stanley Laguna Conference. RXO’s 2026-08-27 announcement schedules management’s appearance for 7:05 p.m. EDT. The event provides a dated opportunity to clarify the September operating update, but the announcement does not promise revised earnings guidance; an appearance without new disclosure would leave the Q3 earnings test unresolved. RXO conference announcement
The Jefferies appearance dated 2026-09-09 has elapsed. A confirmed Q3 earnings-release date is unavailable in the evidence reviewed; the previously estimated date is not treated as a scheduled event.
What Would Change Our Mind
Loss of the September 2 closing low would end the narrower recovery hypothesis: a daily close below $19.79 is the published price condition. Reported Q3 2026 adjusted EBITDA below $35 million would independently break the earnings-continuation argument tied to management’s August 6 guidance.
The positive resolution requires both Q3 adjusted EBITDA of at least $35 million and a weekly close above $24 before that price invalidation occurs. The 2026-09-09 operating update improves the evidence for the earnings requirement; it does not satisfy the market-price requirement.
Correlation Notes
RXO reported on 2026-09-09 that spot freight represented approximately 50% of full-truckload volume during the first two months of Q3. That business mix supports an inferred sensitivity to spot-market economics, but it is not a measured equity correlation. RXO operating update
This remains a single-name recovery hypothesis. The September 9 RXO close and July 31 short-interest snapshot provide no paired peer-return series from which to establish a group move or a stable correlation coefficient.
Notes
- Asset-light broker with low gross margin levered to the truckload spot cycle; earnings power tracks the cycle rather than compounding through it.
- Beta near 1.9: sector and index moves land amplified both ways. The February 2026 session in which the shares fell 20.45% is the magnitude reference.
- the most spot-exposed and most litigation-exposed mix.
- An up-cycle consumes working capital at this model: Q2 2026 disclosure carried a roughly $70M working-capital drag and 4.1x bank-adjusted net leverage.
- Casualty spend of roughly $15–20M a year against a $5M per-occurrence deductible is the only RXO figure publicly quantified against broker-liability exposure.
- RXO is not a party to Lipe v. Lupus Superior — the $604M verdict sits with C.H. Robinson — but the broker cohort's multiple is discounted against its outcome.
Related · shared themes
JBHT
J.B. Hunt Transport Services, Inc.
J.B. Hunt’s freight recovery requires stronger intermodal pricing and continued profit growth at the estimated 2026-10-15 report. Confirmation requires fuel-excluded pricing growth above Q2’s 1% year-over-year increase and rising intermodal operating income before a weekly close below $265 invalidates the structure.
ARCB
ArcBest Corporation
ArcBest’s cost reductions must preserve margins: Q3 2026 recurring savings and an adjusted Asset-Based operating ratio at or below Q2’s 90.8% would confirm the case. A weekly close below $134.45 invalidates the price-supported thesis first.
LSTR
Landstar System, Inc.
Landstar System's truckload repricing needs to produce further earnings improvement. The 2026-10-27 results confirm the case if truck revenue per load grows year over year and earnings per share exceed Q2's $1.44 before a weekly close below $167.
XPO
XPO, Inc.
XPO, Inc.'s shipment-growth story requires continued volume growth and a third-quarter adjusted LTL operating ratio below 81% at the confirmed 2026-10-29 results. A weekly close below $185 invalidates the price case first; the 2026-09-09 daily close of $184.25 already lies below that threshold without establishing a weekly breach.